http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017203367-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b9de45f32319276a1efbfd6d7453643b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2017-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d3ad856e484a687b68a92aac00d7cc6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dbd5b643918cd7b701fdfe30cf825a5 |
| publicationDate | 2017-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2017203367-A2 |
| titleOfInvention | Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof |
| abstract | The present invention is directed to a System characterization of NASH that combines Modeling and Biomarkers, enabling pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of Non Alcoholic Fatty Liver Disease (NAFLD) and Hon Alcoholic Steatohepatitis (NASH). Said conditions are Liver related complications among the array of manifestations of.metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, abdominal obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat inhibit or reduce the likelihood of NASH and NAFLD complications in patients with hepatitis viral infections, including Hepatitis B and Hepatitis C viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, metabolic syndrome complications including cardiovascular diseases, neurodegenerative diseases and premature ageing, among other disease states or conditions. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113599523-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113599523-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109359762-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109359762-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109374890-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108932976-A |
| priorityDate | 2016-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 979.